-
1.
公开(公告)号:WO2020194272A1
公开(公告)日:2020-10-01
申请号:PCT/IB2020/052965
申请日:2020-03-27
申请人: 2681603 ONTARIO INC.
发明人: GUNNING, Patrick T. , OLAOYE, Olasunkanmi , TOUTAH, Krimo , SHOUKSMITH, Andrew E. , SHOUKSMITH, Justyna M. , NAWAR, Nabanita , RAOUF, Yasir S.
IPC分类号: C07C311/19 , A61K31/18 , A61K31/44 , A61K31/4406
摘要: The present application relates to fluorinated benzylsulfonamide hydroxamic acid compounds of Formula I and/or pharmaceutically acceptable salt, solvate and/or prodrug thereof : (I) for use as a inhibitor of HDAC6. The application also relates to methods of treating a disease, disorder or condition using the compounds and compositions of the application.
-
公开(公告)号:WO2018161892A1
公开(公告)日:2018-09-13
申请号:PCT/CN2018/078136
申请日:2018-03-06
IPC分类号: C07C311/46 , C07C303/38 , C07C311/19 , C07C311/39 , C07C311/16 , C07C311/17 , A61K31/18 , A61K31/63 , A61P35/00 , A61P31/12 , A61P25/28
CPC分类号: C07C303/38 , C07C303/40 , C07C311/16 , C07C311/17 , C07C311/19 , C07C311/39 , C07C311/40 , C07C311/46 , C07D317/58 , Y02A50/465
摘要: 一种具有式(I)结构特征的苯磺酰胺类化合物或其药学上可接受的盐、其制备方法、以及它们作为吲哚胺2,3-双加氧酶1(IDO1)抑制剂的用途。实验结果表明,化合物对IDO1的活性具有显著抑制作用,能够有效地促进T细胞增殖,抑制初始T细胞分化成调节性T细胞,逆转IDO1介导的免疫抑制,可以用于治疗具有IDO1介导的犬尿氨酸代谢途径的病理学特征的相关疾病,包括癌症、病毒感染、神经变性疾病、白内障、器官移植排斥、抑郁症和自身免疫性疾病等。
-
公开(公告)号:WO2014135617A1
公开(公告)日:2014-09-12
申请号:PCT/EP2014/054310
申请日:2014-03-06
发明人: FRUTTAROLO, Francesca , PAVANI, Maria Giovanna , BENCIVENNI, Serena , GATTI, Raffaele , NAPOLETANO, Mauro
IPC分类号: C07D213/74 , C07D333/34 , C07C311/19 , C07D213/40 , A61K31/18 , A61K31/381 , A61K31/435 , A61P29/00
CPC分类号: C07D213/56 , C07C311/19 , C07C311/20 , C07D213/40 , C07D213/64 , C07D213/73 , C07D213/74 , C07D213/89 , C07D333/34 , C07D401/04 , C07D409/12 , C07D409/14
摘要: The invention discloses compounds of Formula (I). The compounds of formula (I) are TRPA1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of TRPA1 receptors.
摘要翻译: 本发明公开了式(I)的化合物。 式(I)化合物是TRPA1拮抗剂,可用作药物组合物的活性成分,用于治疗通过抑制TRPA1受体而改善的疼痛和其它症状。
-
公开(公告)号:WO2014066613A3
公开(公告)日:2014-08-28
申请号:PCT/US2013066576
申请日:2013-10-24
发明人: LIU FEIYAN , LIU KEBIN , HUANG ZHIZHEN , WU PING
IPC分类号: C07D217/26 , A61K31/16 , A61K31/404 , C07C233/47 , C07C233/49 , C07C233/52 , C07C233/83 , C07C237/06 , C07C311/19 , C07D209/18 , C07D209/42 , C07D307/68 , C07D307/85 , C07D333/34 , C07D333/38
CPC分类号: C07C237/22 , C07C237/06 , C07C311/19 , C07C2601/16 , C07D209/18 , C07D209/42 , C07D217/26 , C07D307/68 , C07D307/85 , C07D333/34 , C07D333/38
摘要: Sphingolipid metabolite mimetics and methods of synthesizing them are provided. The sphingolipid metabolite mimetics are shown to be effective at inducing apoptosis in various types of tumor cells. Further, the sphingolipid metabolite mimetics are shown to be effective at sensitizing multiple types of tumor cells to TRAIL-induced apoptosis. Formulations containing one or more sphingolipid metabolite mimetics and, optionally, one or more cell death receptor agonists are provided. Methods of treating cancer in a subject in need thereof are provided using one or more sphingolipid metabolite mimetics.
摘要翻译: 提供了鞘脂代谢物模拟物及其合成方法。 显示鞘脂代谢物模拟物在诱导各种类型的肿瘤细胞中的细胞凋亡方面是有效的。 此外,鞘脂代谢物模拟物显示出在多种类型的肿瘤细胞对TRAIL诱导的凋亡敏感方面是有效的。 提供含有一种或多种鞘脂类代谢物模拟物和任选的一种或多种细胞死亡受体激动剂的制剂。 使用一种或多种鞘脂类代谢物模拟物来提供在有需要的受试者中治疗癌症的方法。
-
公开(公告)号:WO2012163815A1
公开(公告)日:2012-12-06
申请号:PCT/EP2012/059802
申请日:2012-05-25
发明人: CASAR, Zdenko , STAVBER, Gaj
IPC分类号: C07C229/34 , C07C239/20 , C07C271/22 , C07C311/19 , C07F7/10 , C07F7/18
CPC分类号: C07C269/06 , C07B2200/07 , C07C227/32 , C07C239/20 , C07C303/40 , C07F7/0892 , C07F7/10 , C07C229/34 , C07C271/22 , C07C311/19
摘要: The invention relates to the preparation of chiral compounds, in particular to the preparation of chiral compounds which may be used as intermediates for the preparation of anti-diabetic agents, preferably sitagliptin.
摘要翻译: 本发明涉及手性化合物的制备,特别是制备可用作制备抗糖尿病药物,优选西他列汀的中间体的手性化合物。
-
公开(公告)号:WO2012047926A2
公开(公告)日:2012-04-12
申请号:PCT/US2011/054812
申请日:2011-10-04
申请人: THE BRIGHAM AND WOMEN'S HOSPITAL, INC. , AUGELLI-SZAFRAN, Corinne E. , LU, Dai , WEI, HanXun , ZHANG, Jing , WOLFE, Michael S. , SELKOE, Dennis J.
发明人: AUGELLI-SZAFRAN, Corinne E. , LU, Dai , WEI, HanXun , ZHANG, Jing , WOLFE, Michael S. , SELKOE, Dennis J.
IPC分类号: C07C311/19 , C07C311/41 , A61K31/18 , A61K31/195 , A61P25/28
CPC分类号: C07C311/16 , C07C311/17 , C07C311/18 , C07C311/19 , C07C311/29 , C07C317/28 , C07C317/32 , C07C323/42 , C07C2601/14 , C07D213/42 , C07D213/71 , C07D263/14 , C07D271/06 , C07D295/32 , C07D333/34
摘要: This invention relates generally to the discovery of sulfonamide-containing compounds that are inhibitors of ϒ-secretase.
摘要翻译: 本发明一般涉及作为γ-分泌酶抑制剂的含磺酰胺化合物的发现。 p>
-
公开(公告)号:WO2010129057A8
公开(公告)日:2011-02-24
申请号:PCT/US2010001350
申请日:2010-05-07
申请人: TETRAPHASE PHARMACEUTICALS INC , CHEN CHI-LI , CLARK ROGER B , DENG YONGHONG , HE MINSHENG , PLAMONDON LOUIS , SUN CUIXIANG , XIAO XIAO-YI
发明人: CHEN CHI-LI , CLARK ROGER B , DENG YONGHONG , HE MINSHENG , PLAMONDON LOUIS , SUN CUIXIANG , XIAO XIAO-YI
IPC分类号: C07C237/26 , C07C275/24 , C07C311/06 , C07C311/19 , C07D205/04 , C07D207/06 , C07D207/08 , C07D209/04 , C07D211/34 , C07D221/20 , C07D223/04 , C07D223/32 , C07D295/03
CPC分类号: C07D471/10 , C07C237/26 , C07C275/24 , C07C311/06 , C07C311/19 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/24 , C07C2602/42 , C07C2602/50 , C07C2603/46 , C07C2603/74 , C07D205/04 , C07D207/06 , C07D207/08 , C07D207/09 , C07D207/10 , C07D207/14 , C07D207/16 , C07D209/04 , C07D209/14 , C07D209/44 , C07D209/52 , C07D211/14 , C07D211/34 , C07D213/74 , C07D221/20 , C07D223/04 , C07D223/14 , C07D223/32 , C07D261/20 , C07D295/13 , C07D295/135 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/26 , C07D307/22 , C07D401/04 , C07D413/06
摘要: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
摘要翻译: 本发明涉及由结构式(I)表示的化合物或其药学上可接受的盐。 结构式I的变量在本文中定义。 还描述了包含结构式I的化合物及其治疗用途的药物组合物。
-
8.
公开(公告)号:WO2011000863A1
公开(公告)日:2011-01-06
申请号:PCT/EP2010/059273
申请日:2010-06-30
发明人: IMFELD, Dominik , WIKSTROEM, Peter , ZIEGLER, Hugo
IPC分类号: C07C311/19 , C07D233/24 , C07D295/185 , C07D403/10 , A61K8/46 , A61K8/49 , A61K31/192 , A61K31/495 , A61K31/505 , A61K31/506 , A61K31/4164 , A61K31/4178 , A61P17/04 , A61Q19/00
CPC分类号: C07D233/24 , C07C311/19 , C07D239/06
摘要: The invention relates to novel sulfonamide derivatives, their preparation as well as to their use as BK 1 antagonists. Furthermore, the invention relates to topical compositions comprising such novel sulfonamide derivatives and their use for the treatment of painful skin sensations as well as sensitive skin and the symptoms associated therewith. Formula (I).
摘要翻译: 本发明涉及新型磺酰胺衍生物,其制备方法以及它们作为BK 1拮抗剂的用途。 此外,本发明涉及包含这种新型磺酰胺衍生物的局部组合物及其用于治疗疼痛皮肤感觉以及敏感皮肤及其相关症状的用途。 式(I)。
-
公开(公告)号:WO2009115257A1
公开(公告)日:2009-09-24
申请号:PCT/EP2009/001888
申请日:2009-03-16
申请人: GRÜNENTHAL GMBH , OBERBÖRSCH, Stefan , REICH, Melanie , SUNDERMANN, Bernd , ENGLBERGER, Werner , HEES, Sabine , JOSTOCK, Ruth , SCHUNK, Stefan , BIJSTERVELD, Edward , THEIL, Fritz
发明人: OBERBÖRSCH, Stefan , REICH, Melanie , SUNDERMANN, Bernd , ENGLBERGER, Werner , HEES, Sabine , JOSTOCK, Ruth , SCHUNK, Stefan , BIJSTERVELD, Edward , THEIL, Fritz
IPC分类号: C07D211/58 , C07D401/04 , C07D401/14 , C07D295/12 , C07C311/17 , C07C311/29 , C07D295/26 , C07D211/96 , C07D207/48 , C07D215/58 , C07C311/19 , A61K31/18 , A61P29/00 , A61P25/02 , A61P37/08
CPC分类号: C07D295/135 , C07C311/17 , C07C311/19 , C07C311/29 , C07C2601/14 , C07D211/58 , C07D401/12 , C07D413/12
摘要: The invention relates to substituted sulfonamide derivatives, processes for the preparation thereof, medicament containing these compounds and the use of substituted sulfonamide derivatives for the preparation of medicaments.
摘要翻译: 本发明涉及取代磺酰胺衍生物,其制备方法,含有这些化合物的药物以及取代磺酰胺衍生物用于制备药物的用途。
-
公开(公告)号:WO2009037497A1
公开(公告)日:2009-03-26
申请号:PCT/GB2008/050769
申请日:2008-09-03
发明人: BLACKER, Andrew John
IPC分类号: C07C303/40 , C07C311/18 , C07C311/19
CPC分类号: C07C269/06 , C07C303/38 , Y02P20/55 , C07C271/20 , C07C271/22 , C07C271/52 , C07C271/54
摘要: The present invention relates to a process for preparing a class of sulphonamides which are aspartyl protease inhibitors. These compounds find therapeutic use in the treatment of the human immunodeficiency virus (HIV). This virus is the causative agent for acquired immunodeficiency syndrome (AIDS). The synthetic procedure of the present invention involves a convenient and efficient process utilising base coupling, decarboxylation and reduction steps to produce the desired compounds in good yield. One advantage of the process of the present invention is its convergent approach which leads to improved yields. The procedure also enables stereoselectivity to be controlled to a high degree, thus avoiding the need for resolution procedures where chiral products are formed.
摘要翻译: 本发明涉及制备一类为天冬氨酰蛋白酶抑制剂的磺酰胺类的方法。 这些化合物可用于治疗人类免疫缺陷病毒(HIV)。 这种病毒是获得性免疫缺陷综合征(艾滋病)的病原体。 本发明的合成方法包括利用碱偶联,脱羧和还原步骤的方便和有效的方法以高产率生产所需化合物。 本发明方法的一个优点是其收敛方法,其导致产量提高。 该程序还能够使立体选择性得到高度控制,从而避免手性产物形成时需要解决程序。 p>
-
-
-
-
-
-
-
-
-